Biotoxtech Past Earnings Performance
Past criteria checks 0/6
Biotoxtech's earnings have been declining at an average annual rate of -4.5%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 9.1% per year.
Key information
-4.5%
Earnings growth rate
-3.9%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 9.1% |
| Return on equity | -18.6% |
| Net Margin | -14.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Biotoxtech (KOSDAQ:086040) A Risky Investment?
May 06
Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)
Mar 28Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?
Feb 20Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?
Jan 24
We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings
Dec 27Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?
Nov 30Revenue & Expenses BreakdownBeta
How Biotoxtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 32,631 | -4,878 | 9,042 | 454 |
| 30 Sep 23 | 34,216 | -5,408 | 10,241 | 332 |
| 30 Jun 23 | 36,638 | -2,487 | 10,434 | 332 |
| 31 Mar 23 | 37,006 | 199 | 10,682 | 72 |
| 31 Dec 22 | 37,292 | 1,278 | 10,833 | 0 |
| 30 Sep 22 | 36,263 | 5,684 | 8,417 | 0 |
| 30 Jun 22 | 35,461 | 5,910 | 7,567 | 0 |
| 31 Mar 22 | 33,976 | 6,462 | 6,425 | 0 |
| 31 Dec 21 | 32,717 | 6,832 | 5,464 | 0 |
| 30 Sep 21 | 31,120 | 3,526 | 5,116 | 0 |
| 30 Jun 21 | 28,570 | 2,633 | 5,135 | 0 |
| 31 Mar 21 | 27,289 | 3,550 | 5,724 | 0 |
| 31 Dec 20 | 26,429 | 2,614 | 5,413 | 0 |
| 30 Sep 20 | 26,306 | 4,237 | 5,135 | 0 |
| 30 Jun 20 | 25,967 | 2,426 | 5,358 | 0 |
| 31 Mar 20 | 25,679 | -1,414 | 5,086 | 0 |
| 31 Dec 19 | 25,854 | -1,482 | 5,056 | 0 |
| 30 Sep 19 | 22,105 | -4,913 | 2,770 | -153 |
| 30 Jun 19 | 23,979 | -1,548 | 3,526 | -153 |
| 31 Mar 19 | 26,632 | 24 | 4,829 | -88 |
| 31 Dec 18 | 27,245 | 4,131 | 5,100 | 0 |
| 30 Sep 18 | 31,567 | 5,261 | 9,270 | 235 |
| 30 Jun 18 | 29,985 | 3,735 | 8,541 | 235 |
| 31 Mar 18 | 27,059 | 4,887 | 7,065 | 170 |
| 31 Dec 17 | 25,565 | 1,392 | 6,297 | 83 |
| 30 Sep 17 | 24,330 | 2,115 | 4,795 | 0 |
| 30 Jun 17 | 23,992 | 1,966 | 4,560 | 0 |
| 31 Mar 17 | 23,196 | 1,584 | 4,468 | 0 |
| 31 Dec 16 | 22,257 | 1,045 | 4,915 | 0 |
| 30 Sep 16 | 20,404 | -1,173 | 6,225 | -10 |
| 30 Jun 16 | 18,932 | -1,942 | 6,051 | 2 |
| 31 Mar 16 | 17,932 | -2,873 | 6,349 | 12 |
| 31 Dec 15 | 16,676 | -3,905 | 6,438 | 23 |
| 30 Sep 15 | 15,384 | -3,790 | 5,280 | 31 |
| 30 Jun 15 | 15,044 | -4,539 | 5,472 | 31 |
| 31 Mar 15 | 14,815 | -4,534 | 5,328 | 32 |
| 31 Dec 14 | 15,088 | -4,528 | 5,987 | 32 |
| 30 Sep 14 | 15,833 | -3,183 | 5,729 | 35 |
| 30 Jun 14 | 15,864 | -2,593 | 5,427 | 23 |
| 31 Mar 14 | 16,015 | -2,084 | 5,270 | 11 |
| 31 Dec 13 | 17,272 | -83 | 4,840 | 0 |
| 30 Sep 13 | 17,392 | 1,022 | 4,829 | 0 |
| 30 Jun 13 | 17,928 | 1,510 | 4,854 | 0 |
Quality Earnings: A086040 is currently unprofitable.
Growing Profit Margin: A086040 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086040 is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.
Accelerating Growth: Unable to compare A086040's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A086040 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.5%).
Return on Equity
High ROE: A086040 has a negative Return on Equity (-18.56%), as it is currently unprofitable.